Navigating Cigna Spravato Prior Authorization
Streamlining the **Cigna Spravato prior authorization** process is critical for ensuring timely patient access to this important therapy for treatment-resistant depression.
For revenue cycle directors and prior authorization coordinators, managing high-volume specialty drug PAs like Spravato with a national payer like Cigna Healthcare presents unique challenges. Understanding specific submission channels, policy requirements, and electronic pathways is key to minimizing delays and reducing administrative burden.
Understanding Cigna's Prior Authorization Channels for Spravato
Spravato, or esketamine nasal spray, often requires prior authorization under both the medical and pharmacy benefits depending on the specific Cigna Healthcare plan and site of administration. Klivira's platform is designed to navigate these distinct pathways, ensuring submissions align with Cigna's operational requirements.
Spravato PA Submission Pathways with Cigna Healthcare
- Medical Benefit: Submissions for Spravato administered in a clinical setting are typically routed through the CignaforHCP.com provider portal or via X12 278 transactions through clearinghouses.
- Pharmacy Benefit: For pharmacy-dispensed Spravato, prior authorizations are managed by Evernorth's Express Scripts, often leveraging ePA platforms like CoverMyMeds and Surescripts.
- Specialty Pharmacy: Accredo, a specialty pharmacy under Evernorth's Express Scripts, may handle PAs for specialty injectables and complex medications like Spravato when dispensed through their network.
- Policy-Specific Requirements: Cigna's medical and pharmacy policies for Spravato will dictate clinical indications, site-of-care, and step therapy requirements.
Cigna's Utilization Management Policies for Spravato
Cigna Healthcare publishes detailed medical necessity guidelines and coverage policies on its public provider site, cigna-coverage-positions. These policies outline the specific clinical criteria, required preceding therapies, and documentation necessary for Spravato approval, often referencing Cigna-developed criteria or external sources.
Electronic Prior Authorization (ePA) for Cigna Spravato
Cigna Healthcare actively participates in the HL7 Da Vinci Project ecosystem, indicating a commitment to advancing electronic prior authorization. For pharmacy benefit Spravato PAs, Evernorth's Express Scripts has well-established ePA capabilities through partners like CoverMyMeds and Surescripts, streamlining prescriber-initiated workflows.
Common Denial Reasons and Appeal Pathways for Spravato with Cigna
Denials for Spravato prior authorizations from Cigna Healthcare often stem from insufficient documentation, failure to meet step therapy requirements, or non-adherence to formulary guidelines. Klivira helps identify these patterns, facilitating proactive adjustments or efficient initiation of Cigna's documented appeal pathways, including peer-to-peer reviews for clinical denials.
Turnaround Time Considerations for Cigna Spravato PAs
Turnaround times for Cigna Spravato prior authorizations are influenced by state-specific regulations for commercial plans and CMS-0057-F requirements for Medicare Advantage plans, which mandate 72-hour standard and 24-hour expedited PA timeframes. Klivira's automation helps track and prioritize submissions to meet these critical deadlines.
Frequently asked questions
How do I submit a prior authorization for Spravato to Cigna Healthcare?
Submissions for Cigna Spravato prior authorization depend on the benefit. For medical benefits, use CignaforHCP.com or X12 278. For pharmacy benefits, Express Scripts (Evernorth) manages PAs, often via CoverMyMeds or Surescripts ePA.
What are the typical reasons for a Cigna Spravato prior authorization denial?
Common denial reasons include insufficient clinical documentation, failure to demonstrate compliance with Cigna's step therapy requirements, site-of-service mismatches, or issues related to the Express Scripts formulary.
Does Cigna Healthcare require step therapy for Spravato (esketamine)?
Cigna's coverage policies for Spravato typically include step therapy requirements, mandating documentation of previous trials with other antidepressant therapies before Spravato is approved. Always consult the latest Cigna policy for specific criteria.
Which PBM handles Spravato prior authorizations for Cigna members?
Evernorth's Express Scripts is the Pharmacy Benefit Manager (PBM) that handles pharmacy benefit prior authorizations for Cigna Healthcare members, including for specialty medications like Spravato. Accredo, an Express Scripts specialty pharmacy, may also be involved.
What are the expected turnaround times for Cigna Spravato prior authorizations?
Turnaround times vary by plan type and state. For Cigna Medicare Advantage plans, CMS-0057-F mandates 72-hour standard and 24-hour expedited PA decisions. Commercial plan timeframes are subject to state insurance regulations.
Related coverage
Other spravato prior authorization by payer
- Navigating Aetna Spravato Prior Authorization
- Navigating Anthem (Elevance Health) Spravato Prior Authorization
- Streamlining Humana Spravato Prior Authorization
- Streamlining Medicaid Spravato Prior Authorization Workflows
- Streamlining Medicare Spravato Prior Authorization
- Navigating UnitedHealthcare Spravato Prior Authorization
Other spravato prior authorization by specialty
- Streamlining Spravato Prior Authorization for Cardiology Practices
- Navigating Spravato Prior Authorization for Endocrinology Practices
- Spravato Prior Authorization for Gastroenterology: Navigating Complexities
- Optimizing Spravato Prior Authorization for Oncology Patients
- Optimizing Spravato Prior Authorization for Orthopedics
Ready to automate prior auth for this drug?
See how Klivira automates prior authorizations for your team.
Request a demo